{
  "guideline": {
    "id": "PA166104998",
    "name": "Annotation of CPIC Guideline for nortriptyline and CYP2D6",
    "source": "CPIC",
    "version": 54,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104998",
    "relatedChemicals": [
      {
        "id": "PA450657",
        "name": "nortriptyline",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166301325",
      "name": "Recommendation Annotation PA166301325",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095644,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298259",
      "name": "Recommendation PA166298259",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060861,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of tricyclic antidepressants"
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298254",
      "name": "Recommendation PA166298254",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060856,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298267",
      "name": "Recommendation PA166298267",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060869,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298250",
      "name": "Recommendation PA166298250",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060852,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298260",
      "name": "Recommendation PA166298260",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060862,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of tricyclic antidepressants"
      ],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298255",
      "name": "Recommendation PA166298255",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060857,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "2.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298268",
      "name": "Recommendation PA166298268",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060870,
        "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2D6: Greatly reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298207",
      "name": "Recommendation PA166298207",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060809,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298264",
      "name": "Recommendation PA166298264",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060866,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298261",
      "name": "Recommendation PA166298261",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060863,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of tricyclic antidepressants"
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298200",
      "name": "Recommendation PA166298200",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060802,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298213",
      "name": "Recommendation PA166298213",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060815,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298256",
      "name": "Recommendation PA166298256",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060858,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298269",
      "name": "Recommendation PA166298269",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060871,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Because CYP2D6 phenotype could not be assigned based on genotyping performed, therapuetic monitoring should be considered. If therapuetic monitoring cannot be performed, monitor closely for toxicity and/or efficacy.</p>\n"
      },
      "implications": [
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298252",
      "name": "Recommendation PA166298252",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060854,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298265",
      "name": "Recommendation PA166298265",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060867,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298258",
      "name": "Recommendation PA166298258",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060860,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of tricyclic antidepressants"
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298249",
      "name": "Recommendation PA166298249",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060851,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298266",
      "name": "Recommendation PA166298266",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060868,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298257",
      "name": "Recommendation PA166298257",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060859,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298262",
      "name": "Recommendation PA166298262",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060864,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of tricyclic antidepressants"
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298253",
      "name": "Recommendation PA166298253",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450657",
          "name": "nortriptyline",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060855,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "27997040",
      "title": "Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.",
      "authors": [
        "Hicks J K",
        "Sangkuhl K",
        "Swen J J",
        "Ellingrod V L",
        "Müller D J",
        "Shimoda K",
        "Bishop J R",
        "Kharasch E D",
        "Skaar T C",
        "Gaedigk A",
        "Dunnenberger H M",
        "Klein T E",
        "Caudle K E",
        "Stingl J C"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2017
    },
    {
      "pmid": "23486447",
      "title": "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.",
      "authors": [
        "Hicks J K",
        "Swen J J",
        "Thorn C F",
        "Sangkuhl K",
        "Kharasch E D",
        "Ellingrod V L",
        "Skaar T C",
        "Müller D J",
        "Gaedigk A",
        "Stingl J C",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2013
    }
  ],
  "version": "2023-12-19-10-38"
}